Greenlight Capital Proclaims Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS – Amgen (NASDAQ:AMGN)

Within the newest funding strikes, Greenlight Capital GLRE, led by David Einhorn, has disclosed its Q2 2025 13F submitting trades.

The hedge fund has established new stakes in Fluor Corp. FLR and Victoria’s Secret & Co. VSCO, whereas exiting its place in Varex Imaging Corp. VTRS.

Greenlight Capital’s Q2 2025 13F submitting reveals that the hedge fund purchased 760.6K shares of Fluor Corp. and 168.3K shares of Victoria’s Secret & Co.

Concurrently, Greenlight determined to half methods with Varex Imaging Corp. The fund additionally made important changes to its present stakes, including to its shares in Albireo Pharma Inc. ABIO and Amgen Inc. AMGN, whereas decreasing its holdings in Activision Blizzard Inc. ATVI and Bristol Myers Squibb Co. BMY.

Additionally Learn: Buffett’s Inventory Gross sales Level To Overvalued Market, Says Hedge Fund Supervisor David Einhorn: ‘Not A Nice Time To Have A Lot Of Fairness Publicity’

Greenlight Capital’s Q2 2025 trades present an perception into the hedge fund’s funding technique and market outlook. The brand new positions in Fluor and Victoria’s Secret point out a possible confidence in these firms’ future efficiency.

The exit from Varex Imaging, alternatively, may counsel a much less optimistic view of the corporate’s prospects.

Moreover, the changes to Greenlight’s present stakes mirror the fund’s dynamic funding method, geared toward optimizing returns.

The elevated stakes in Albireo Pharma and Amgen counsel a optimistic outlook for these biopharmaceutical firms, whereas the decreased holdings in Activision Blizzard and Bristol Myers Squibb may point out a extra cautious stance in direction of these companies.

Learn Subsequent

David Einhorn Says Inventory Market Is Basically Damaged: Right here’s Why

Picture: Shutterstock/Trong Nguyen